Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study
Keyword(s):
Phase Ii
◽
2012 ◽
Vol 7
(1)
◽
pp. 157-164
◽